Good morning and welcome to Acadia Healthcare's Fourth Quarter and Full Year 2022 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded today. I would now like to turn the conference over to Gretchen Hommrich. Please go ahead ma'am.

Good morning and welcome to Acadia's fourth quarter 2022 conference call. I'm Gretchen Hommrich, Vice President of Investor Relations for Acadia. I'll first provide you with our Safe Harbor before turning the call over to our Chief Executive Officer, Chris Hunter. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements among others regarding Acadia's expected quarterly and annual financial performance for 2022 and beyond. You are hereby cautioned that these statements may be affected by the important factors among others set forth in Acadia's filings with the Securities and Exchange Commission and in the company's fourth quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. At this time for, opening remarks, I would like to turn the conference call over to our Chief Executive Officer, Chris Hunter.

Thank you, Gretchen. Good morning everyone and thank you for being with us today for our fourth quarter 2022 conference call. I'm here today with Chief Financial Officer, David Duckworth; and other members of our executive management team. David and I will provide some remarks about our financial and operating performance for the fourth quarter of 2022 and guidance for 2023. Following our comments, we'll open the line for your questions. In December, we held our first ever Investor Day at Carnegie Hall in New York and we're appreciative that so many of you joined us in person and through our webcast. It was a great event and we appreciate your support. I'm pleased to say that our fourth quarter results and start to 2023 demonstrate that we're executing on the strategy we presented with favorable results across our key performance metrics. Throughout the past year, we continued to see strong momentum in our business, reflecting robust demand for our behavioral health care services. We need to continue to commend our dedicated team of employees and clinicians across our operations who have worked tirelessly to meet the needs of those seeking treatment for mental health and substance use issues. Our strong results reflect our ability to effectively operate our 250 facilities across Acadia's network and serve our patients with safe, quality care. During the fourth quarter, we continued to see positive trends in our business with an increase in our same facility revenue of 9.4% compared with the fourth quarter of 2021 including an increase in revenue per patient day of 5.2% and an increase in patient days of 4.0%. Our fourth quarter results marked a strong finish to 2022 and we believe set us up well for 2023. We are proud of our vitally important work to support expanding…

Thanks, Chris, and good morning. Looking at the fourth quarter, we delivered strong financial and operating results, as we successfully delivered on our key performance metrics, demonstrating consistent execution of our strategy. Revenue for the fourth quarter of 2022 increased 13.8% to $675.3 million compared with $593.5 million for the fourth quarter of 2021. Our revenue growth includes an increase in same facility revenue of 9.4%. For the fourth quarter, our adjusted EBITDA was $150.9 million and adjusted income attributable to Acadia stockholders per diluted share was $0.74, which includes income of $5.2 million related to the provider relief fund also related to the American Rescue Plan payments. Adjusted -- adjustments to income for the fourth quarter of 2022 include transaction-related expenses and the related income tax effect. The company also recorded an unfavorable adjustment of $5.9 million, or $0.05 per diluted share to its self-insured professional and general liability reserves relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017 to 2018 period. The estimated accrual for professional and general liabilities is based on historical claims, prior settlements and judgments and other factors and actuarial assumptions. While we could see volatility in this reserve due to our self-insured retention level of $5 million, we view this fourth quarter adjustment as a non-recurring item relating to unique facts and circumstances for certain claims in that 2017 to 2018 period. From a cost management perspective, we were pleased with our execution throughout 2022. While we saw higher wage inflation in 2022, including approximately 8% base wage inflation for the fourth quarter we believe it's important to remain proactive in our pay and our volume and reimbursement growth have remained strong. While base wage inflation is expected to remain higher in the 7% to 8%…

We will now begin the question-and-answer session. [Operator Instructions] And our first question will come from A.J. Rice with Credit Suisse. Please go ahead.

Thanks. Hi, everyone. I know -- at the Investor Day and then in your comments today you've talked about a little bit about the potential acquisition pipeline that's out there for you. I wondered if you'd expand a little more on what you're seeing. It seems like there's a lot of JV and potential acquisition opportunities coming out of pandemic. Is that still there? And then is there any opportunity you think this year as you look out for larger deals are there any of those potentially out there?

Yes. Thanks, A.J. This is Chris and I'll start. We continue to feel very optimistic about the M&A pipeline, which is clearly one of our important growth levers for 2023. I would say that we have done extensive work in looking at the underbedded markets and really targeting the MSAs where we believe we have the most upside potential over time. So we have -- we're always looking to find ways to optimally deploy capital whether that is doing more JVs, doing de novos, clearly looking at M&A. And right now we feel very good about the pipeline that we have on the M&A front. And I feel also that we have some confidence that valuations are slightly softening as we're heading here into the New Year. I would say to your question on the JV front, we also feel very strong about the pipeline there. Our existing JV announcements are expected to take us from our current acute states of 21 plus Puerto Rico into three additional states; Colorado, Minnesota and North Carolina. And then the pipeline of near-term deals on the JV front are expected to take us into two additional states. And I think really just strengthen our geographic footprint overall. So we feel very good about the pipeline that's building in these MSAs on the JV front certainly with de novos and definitely with M&A as well.

Okay. Great. And maybe my follow-up. Obviously, the 9.4% revenue increase is a robust number. I wonder, if you could give us a little flavor for -- across the individual segments. Was that a consistent rate of growth, or was there much variation across your key business loans?

Yes, A.J. we were pleased with the same-facility revenue performance in the quarter, which included another strong quarter of revenue per day growth and our strongest quarter of the year from a volume perspective. And as we look at that by service line we saw incredibly strong performance demand, volume pricing really across all of the service lines but we would highlight acute specialty and the CTC business all saw a very strong quarter. RTC also performed well very stable. Of course, there are fewer investments going into that service line, but the facilities we have had a very good 2022 and fourth quarter, but acute specialty and CTC really led the charge in terms of revenue growth for the quarter.

And I would just add -- for 2023, we really continue to expect strong patient day growth of 4% to 6% for the year. And I would say that the volume is supported by three things. The first is just our strong demand that continues. The second would be the important capacity additions that we've seen and that we just discussed in the second half of 2022 that will continue into early 2023. And then the third is just the improved performance that we're starting to see from optimizing our marketing and admissions processes. So it's early in the year. But so far into the quarter, we're seeing record census and patient day growth that we really think at the higher end of the 4% to 6% that we're projecting for the year.

Okay, great. Thanks so much.

And our next question will come from Whit Mayo with SVB Securities. Please go ahead.

Hey. Thanks. Maybe for David or actually more for Chris. When you guys look at the capital that you're deploying have you changed at all or refined how you measure returns on capital? I'm just wondering how the returns have changed on these deals and what your minimum hurdle rates are today? And it might just be more helpful to frame from like a cohort perspective how capital returns are tracking?

We always refine how we think about allocating capital across our growth pathways, across our service lines and haven't necessarily changed how we think about our targets. Certainly like a lot of companies would say our weighted average cost of capital and the cost of debt has increased slightly. But from our perspective, we've always built in a higher threshold that we target in our transactions such that we haven't had to significantly change how we think about that capital allocation. We continue to think that our existing facility expansions are our most attractive opportunity. And then as we think about de novos and as we think about joint ventures and even M&A opportunities, we have a deal specific analysis that we look at. But across those growth pathways, we're still seeing good opportunities that exceed the hurdles that we have in place across a number of different metrics, IRR. We look at ROIC. We look at our EBITDA multiple not only at the time that we make an investment. But over the course of the investment as we hope to grow earnings whether that's an M&A deal or a de novo or a joint venture facility. So no major changes, of course, as we projected out in December. There are many joint venture projects that we think will be tremendous for the company that we're working hard to bring online and bring good EBITDA growth for the company at strong returns. But we think all pathways will have activity that is going to be attractive.

We get the question a lot around redeterminations, and I presume that most of your Medicaid is in the adolescent population and many of those that would lose traditional Medicaid coverage may just flip into chip. It might just be helpful to hear some of the work that you guys have done internally and how you might be thinking about how that plays out over the course of 2023? Thanks.

Yeah, Whit we've been focused on this topic as it's certainly been out there and now is I guess closer to being implemented across the different states than it was as we thought about the potential of it happening over the course of last year. But we've had a lot of time to plan. As we've talked about previously, we really view mental health coverage as essential and think that many states and payers would intend to continue to provide coverage. But, of course, we want to help all of our Medicaid patients navigate what that means for them whether it's an administrative process that they go through to reenroll in their Medicaid plans or find some other product. Our focus has been on educating our patients, our facilities, our operations leaders, our revenue cycle leaders have done a tremendous job just planning for that and communicating what to expect as we move into the second quarter. We'll continue to monitor the potential impact. Of course there are patient populations as you mentioned, the child and adolescent population that I think is less likely to have a disruption and will have a longer period of time where they can stay enrolled in Medicaid. But we want to help all of our patients just navigate what it means for their coverage through the year and the team has done a nice job preparing.

Okay. Thanks guys.

Our next question will come from Kevin Fischbeck with Bank of America. Please go ahead.

Okay, Great. Thanks. I just wanted to follow-up on some of your labor comments because I think last quarter you had talked about kind of 5% to 7% wage growth and it seems a little bit optimistic that you see some moderation in that number over time back to the 3% to 4% number. So I just want to get a little more color on kind of why it was so much higher in Q4 when most of the companies seem to be saying that they're seeing some progress on labor?

Yeah, Kevin, we did see 5% to 7% over the first three quarters of the year. The third quarter was around that 7% level. The fourth quarter as we isolate just base wage inflation, we were around 8% which we view as pretty similar to the 7% that we saw in the third quarter. We do want to remain proactive with our pay. So we're seeing an improved environment as we look at just our recruiting metrics, as we look at our net new hires which improved throughout the fourth quarter and in January and the weekly data that we have for February. And so we're seeing some positive signs of improvement. We do have for the company our annual merit increase process that happens either in January for two-thirds of the company or in April for the other one-third of the company. And we want to remain committed to that and stay in the right place from a pay perspective across our markets. So we have moved forward with that. And partially because of that expect wage inflation to stay in that 7% to 8% range through the first half of this year. But with some of those positive metrics that we're seeing with the improvement that we mentioned in premium pay that we saw in the fourth quarter we're seeing some positive signs. And I think as we look out at the second half of the year, we would see wage inflation and our outlook reflects wage inflation dropping back down below the 5% level. We'll ultimately see if it returns to more of the 3% to 4% that the company saw for a number of years and the industry saw for a number of years. But for now, second half of the year we think we would moderate at that point to less than 5% on a base wage inflation. And then premium pay, we think continues to improve throughout the year.

Okay. I think last quarter you kind of broke out some of the labor pressure from things like CenterPoint. Is there anything like that kind of skewing the metrics at all from ramp-up of newly opened facilities? And I guess has labor sourcing had all been a headwind to volume growth? Are you having a hard time staffing, or is it just you can staff you just have to pay up for it? Thanks.

I appreciate the question on the metrics. We would say as you look at our labor metrics including salaries, wages and benefits as a percentage of revenue, we did have a $4 million pickup that we recorded and highlighted in the fourth quarter of last year relating to the direct payment program in the state of Florida. And so that did lower our SWB metric by 30 basis points. And then of course, depending on what metric you're looking at here in the fourth quarter of this year, if it's margin, it's impacted by the reserve adjustment that we highlighted. So we do have some adjustments that need to be made as you think about the year-over-year metrics given that. And within that, we would say our same facility group is performing very well. It's stable year-over-year and is seeing margin improvement year-over-year. But there are three new facilities that we've opened in the second half of 2022 that do carry a much higher labor load as their volume and revenue ramps. So that did have an impact on both the SWB metric as well as our margin. CenterPoint perform well in the fourth quarter. We saw that just the team overseeing their integration, do a fantastic job throughout the year, bringing improvements to the performance of that acquisition. But it did also have an impact on our margin as -- from the acquired date and even in the fourth quarter that business has a lower margin than the company average. So there's a few items like that that did impact our labor metrics and some investments we've made at the corporate level, which are having a positive impact on the company as we move into 2023 also are reflected in that SWB and in the margin.

Great. Thanks.

Our next question will come from Andrew Mok with UBS. Please go ahead.

Hi, good morning. Chris, you mentioned some new investments and facility openings in your prepared remarks, but it wasn't entirely clear to me what changed versus the previous outlook. Can you help us better understand what specifically is driving the higher revenue outlook for 2023? And why that's causing a narrowing of the EBITDA range at this stage? Thanks.

So Andrew, just to clarify, you're looking for more detail on the IT investments?

Just the 2023 revenue outlook versus the previous outlook you gave at the Investor Day. And why that's causing a narrowing of the EBITDA range at this stage?

Yes. I mean Andrew, we of course did provide initial guidance – and this is David. We have provided initial guidance in December, earlier than the company typically provides our guidance. And we did as we updated that guidance in February, really viewed de novo range as a tightening of what we provided in December. I'll say since December, as we've gone through and finalized our budgeting process as we've also seen trends through the fourth quarter and the start that we've had to Q1, we did increase our revenue outlook. And the key driver of that is that we see our volume accelerating. We talked about the 4% same facility volume growth for the fourth quarter, now accelerating for 2023 to a range of 4% to 6%. And we are starting Q1 at the high end of that 4% to 6% range. So we're really pleased with the volume outlook, and it is slightly stronger than what we had projected in December, given some of those strong trends to start the year. The EBITDA outlook, we do believe that that incremental volume drives incremental EBITDA as well. But our view is for now given it's early in the year, we just tightened our EBITDA range but kept the midpoint where it was. And of course, things like wage inflation have also been factored in just the updated view around that compared to projections that we had in December. Hopefully that helps.

Got it. That's helpful. And then on the CapEx, I think it's been about two years in a row now where you've cut the growth CapEx about $85 million lower versus initial expectations with the step-up in growth CapEx $375 million this year. What's your confidence level in getting that completed this year? Thanks.

Well it's a good question because as we talked about throughout 2022, we have been looking forward to breaking ground across all of those new facilities that we've had in the pipeline just ready to start construction and work towards the opening of those new joint ventures and other facilities and didn't have as much visibility a year ago, as we talked about our CapEx guidance as we feel like we have today. There are a number of projects that have now broken ground. And at that point, we do have higher visibility and have a higher confidence level. And so we're expecting for that step-up to occur and that's reflected in our guidance. And we'll continue to provide an update as to the timing of those projects. But we're glad to be at this moment where we feel like we have higher visibility because the opportunity we have to get those facilities open and bring them into the company, we think is a key driver for our results, two, three years from now. So I'm not going to give you a percentage confidence level but we do have much higher visibility today, given that we've broken ground across many of those projects.

Great. Thanks for the color.

Yes, thanks, Andrew.

Our next question will come from Gary Taylor with Cowen. Please go ahead.

Hey, good morning. I had a question. I noticed in the release and you talked about this at Investor Day, a little bit about the opportunity to add the intense outpatient programs at some of your IPF. So the question was how many of your IPFs have all three or also include partial hospitalization and the intense outpatient programs? And is there a way to sort of size the remaining revenue opportunity, either per facility or just for the total company to build out those step-down programs across all the acute hospitals.

Yes. Thanks, Gary, for the question. This is Chris. So I would say, a majority of our acute facilities, certainly, have the opportunity for step-down programs and that's something we haven't disclosed the exact number. Clearly, that is a focus of our clinical team led by our Chief Medical Officer, Mike Genovese, as we're trying to continue to -- we've added obviously that fifth growth pathway around PHP and IOP, also looking to enhance the cross-referral opportunity within the company as well. But, David, anything you would want to add on step-down programs?

No. We have seen a number of new programs opened over the years. And our team has done a nice job really looking at where our patients are coming from, where we might be deflecting patients based on the level of care that's appropriate for them and where they might be stepping down and really using that to open new programs. And it also informs our de novo strategy, just as we think about where we might have a service gap. So happy to bring on a number of new programs at our existing facilities, but it's also really being informed and useful as we think about the de novo growth and other opportunities where the company might need to add capacity.

Could I just do a quick follow? Could you give us a sense of you have an IPF that doesn't have those two step-down programs. You have an IPF that has kind of mature step-down programs, is the revenue differential, is it 10% higher 20% higher? Can you give us any sort of sense on what those step-down programs add to the facility profile?

We would probably be ballparking it right now. But I think that 10% range is probably about right, depending on the size of their program. In some cases the facility could have a strong program that's not only stepped down. It's also capturing other patients in that market that may just need a different level of care. So it does vary by facility, but 10% may be the right estimate.

Thank you.

Thanks, Gary.

Our next question will come from Pito Chickering with Deutsche Bank. Please, go ahead.

Hi, there. You've got Kieran Ryan on here for Pito. Thanks for taking the question. I was just wondering if you could maybe break out the SMB impact in 4Q from the one-time reserve adjustment. And then I have a quick follow-up after that.

Yes. The -- as we think about the SWB impact from the reserve adjustment, where that adjustment went on our P&L was actually in other operating expenses, which is where we have our interest expense. And so, just thinking about it more from a margin perspective and other operating expenses, that metric as a percentage of revenue for the fourth quarter was 13.9%. And without that reserve adjustment, would have been 13.0%. So that's the impact that it had on that line item and had about a 0.9% impact on margin as well.

That's helpful. Thank you. And then, just on the 2023 EBITDA outlook, could you just -- are you able to break out how much of the change there is due to discretionary investments and facility openings versus just the wage pressure, which seems to kind of hold in pretty high there in 4Q in the high single digits? Thank you.

Yes. I mean, our expectation continues to be for those new facilities which do carry some startup losses in the near-term, but are an important driver of longer-term value creation and earnings growth for the company. But our expectation for 2023 is that, those new facilities would still be in the $15 million to $20 million range in terms of where their start-up losses should run. That always depends on just the timing and number of new facilities that we have. But that $15 million to $20 million continues to be our estimate for annual start-up losses of our new facilities.

Thank you.

Thank you.

And our next question will come from John Ransom with Raymond James. Please go ahead.

Hi. Good morning. Just a couple on the reimbursement side, I have one and then a follow-up. So, if we're looking at apples-to-apples just pure rate, 2023 over 2022, how should we think about just the pure rate updates affecting your revenue per day percentage growth? Thanks.

Yes. John, we have a -- I'd say, compared to December, we have a more positive outlook around reimbursement. Of course, we always go in with expectations for rate increases in the mid-single-digit range. It's what we've seen throughout 2022. And based on inflation and other factors, I expect to see that for most of our payers going forward. But I want to remain cautious, just knowing, we have a lot of different payers that we contract with. But as we have more recently just thought about what the year looks like from a revenue per day perspective, we are expecting on average 3% to 5%, but do feel like in the early part of the year we have a higher level of visibility that we should sustain growth in the higher end of that range so closer to that 5%. The reason for that is a lot of our contracting with Medicaid plans. Over 75% actually of our Medicaid revenue is contracted in the second half of the year which means, as we go through the first part of this year, we can see the rate increases that we received over the second half of the year that carry into the first half of this year. And then the focus is on, renegotiating with those payers in advance of next year's contract date. So I do feel like we have higher visibility now. We saw a lot of success across our different facilities markets and payers throughout 2022. And hope that that continues in the mid-single-digit range and have visibility we think that it will through the first part of the year. A little more caution just built into the second part of the year where we may see it at the lower-end, but we'll obviously stay focused on that. I think we still have opportunities just building some caution into our outlook for the later part of the year.

And John, I would just add that, to David's point, we have a very strong corporate managed care team that I think has continued to just build and enhance really good relationships with payers across the board and has for a number of years. We've chosen to invest in that team. And I think that really factors into some of the comments that David made. But we do want to be cautious about, how all of this comes together and just the overall impact for the company in total.

And my follow-up is, in theory as you talk to your commercial and Medicaid partners about value-based kickers use the baseball analogy kind of where are you? And then just in theory, what would that look like for behavioral because we're not used to being very common in your world. Thanks.

Yes. So to use your baseball analogy John, I would say, we're approaching first space very early innings here. There -- we want to be in a position strategically, and we are doing so with these IT investments that we're prepared to move at the pace that the industry will move, on behavioral health. It's one of the major reasons that we feel so strongly, about getting all this infrastructure in place, making sure that we are able to capture data and that we can ultimately compete on the quality of the clinical outcomes that we're achieving relative to our competitors. But I think, in terms of value-based programs. It depends on the payer. And we certainly, are seeing some interest from payers here in the early stages that they are willing to provide us with some incentives. Usually, it's around readmissions and successfully preventing readmissions, but there are other factors that will probably be added to that over time. But these contracts right now that we're seeing, are just much more upside-only contracts. We are not seeing any contracts or any interest right now, in downside risk or certainly any move to full capitation. So that's why I would say, we're still approaching first space. And if we, accelerate our pace here to second or third, we'll be ready given the investments that we're making and that's how we want to position ourselves to move at that pace.

So, Chris to be clear baseball you're supposed to talk about innings you know, on that basis, but that's okay. I get a second inning then, right?

Sure. I tried to give you both.

That’s good. All right. Thanks so much.

This concludes our question-and-answer session. I'd like to turn the conference back over to Chris Hunter, for closing remarks.

Well, thank you. Before we end the call, I just want to thank again our committed facility leaders, clinicians and approximately 23,000 dedicated employees across the country, who have just continued to work tirelessly, to meet the needs of patients in a safe and effective manner. I want to thank you all, for being with us this morning and for your interest in Acadia. And if you have any additional questions today, please don't hesitate to contact us directly. Have a great day everyone.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.